<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660786</url>
  </required_header>
  <id_info>
    <org_study_id>0304857</org_study_id>
    <nct_id>NCT04660786</nct_id>
  </id_info>
  <brief_title>Intralesional Vitamin D in Alopecia Areata</brief_title>
  <official_title>Intralesional Vitamin D3 Injection in Treatment of Alopecia Areata: A Novel Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of intralesional injection of vitamin D3 versus&#xD;
      intralesional injection of corticosteroids in treatment of alopecia areata.&#xD;
&#xD;
      this will be carried out on 40 patients who attend hair outpatient clinic, department of&#xD;
      dermatology, Faculty of medicine, Alexandria University, Egypt.&#xD;
&#xD;
      The patients will be randomly assigned into two groups (A and B), each group contains 20&#xD;
      patients. Patients will be blindly subjected to intralesional injection of triamcinolone&#xD;
      acetonide (5mg/ml) using sterile saline for dilution every 4 weeks for 3 sessions (11,12) or&#xD;
      intralesional injection of vitamin D (an aqueous preparation of cholecalciferol (Devarol®&#xD;
      ampoule 200,000 IU/2 mL, Memphis, Egypt) (2.5 mg/mL) every 4 weeks for 3 sessions. The&#xD;
      maximum total amount of vitamin D3 injected into a patient in 1 session will be 5 mg&#xD;
      Injection will be preceded by topical anaesthesia under occlusion for 30 minutes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regrowth Score (RGS)</measure>
    <time_frame>three month</time_frame>
    <description>calculation at week 12 using a 5-point semiquantitative score (RGS)(0 = regrowth &lt; 10%; 1 = regrowth 11- 25%; 2 = regrowth26 - 50%; 3 = regrowth 51- 75%; 4: regrowth &gt; 75%)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>intralesional injection of triamcinolone acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg/ml) using sterile saline for dilution every 4 weeks for 3 sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intralesional injection of vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(2.5 mg/mL) every 4 weeks for 3 sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
    <description>local immunosuprresent</description>
    <arm_group_label>intralesional injection of triamcinolone acetonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>local immunomodulator</description>
    <arm_group_label>intralesional injection of vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Site: scalp. Extent: localized alopecia areata (less than 50% scalp involvement).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other skin diseases affecting the scalp&#xD;
&#xD;
          2. Pregnant or lactating women.&#xD;
&#xD;
          3. Bleeding or coagulation disorders&#xD;
&#xD;
          4. Immunocompromised patients.&#xD;
&#xD;
          5. Known hypersensitivity to vitamin D3.&#xD;
&#xD;
          6. Patients who received systemic or topical treatment for alopecia areata in the last&#xD;
             month.&#xD;
&#xD;
          7. Patients taking vitamin D supplements in the last 6 months.&#xD;
&#xD;
          8. Patients treated with topical vitamin D analogues.&#xD;
&#xD;
          9. Patients with diseases known to alter vitamin D level as autoimmune diseases, liver or&#xD;
             renal diseases.&#xD;
&#xD;
         10. Obesity (defined as body mass index ≥ 25).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>marwa eldeeb</last_name>
    <phone>01200029774</phone>
    <email>marwa.eldeeb16@alexmed.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21521</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>marwa eldeeb</investigator_full_name>
    <investigator_title>lecturer of dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

